Drug Patent Watch

FEBRUARY 13, 2025

The Unsung Heroes of Generic Drug Development: The Power of Partnerships As we navigate the complex landscape of pharmaceuticals, it's easy to overlook the crucial role that partnerships play in bringing affordable, life-saving medications to market. When it comes to developing generic drugs, partnerships can take many forms.

Drug Development 83

Drug Development Drugs Pharmaceutical Companies Treatment 83

Collaborative Drug

AUGUST 1, 2023

Streamlining Collaborations and Drug Development using CDD Vault and ELN

Drug Development 241

Drug Development Drugs 241

BioPharma Drive: Drug Pricing

FEBRUARY 2, 2024

The California biotech is the third this year to go public, following stock offerings from CG Oncology and Arrivent Biopharma.

Drug Development 326

Drug Development Drugs 326

Drug Patent Watch

FEBRUARY 12, 2025

Accelerating Generic Drug Development: Strategies for Success As a pharmaceutical professional, you know how crucial it is to navigate the complex landscape of generic drug development. The generic drug development process involves several stages, from patent research to regulatory approvals.

Drug Development 81

Drug Development Drugs Compliance Regulations 81

BioPharma Drive: Drug Pricing

OCTOBER 14, 2024

The deal would hand Lundbeck a treatment for a series of rare brain disorders that could, by the company's estimates, become a blockbuster product.

Drug Development 293

Drug Development Treatment Production Drugs 293

BioPharma Drive: Drug Pricing

JANUARY 13, 2025

Intra-Cellular has had success selling Caplyta, a brain-rebalancing drug that's approved to treat schizophrenia and bipolar depression.

Drug Development 253

Drug Development Drugs 253

BioPharma Drive: Drug Pricing

SEPTEMBER 13, 2023

The biotech is telling investors it expects to launch as many as 15 new products in five years, a bold goal that will require a lot to go right to pull off.

Drug Development 291

Drug Development Production Drugs 291

BioPharma Drive: Drug Pricing

OCTOBER 30, 2023

The venture firm has supported a number of approved medicines with its co-development strategy, including Pfizer’s Besponsa and Apellis’ Empaveli.

Drug Development 273

Drug Development Drugs 273

PPD

OCTOBER 31, 2024

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. In response, the PPD clinical research business of Thermo Fisher Scientific conducted its third global survey of 150 drug developers to capture a comprehensive view of these evolving trends.

Drug Development 52

Drug Development Clinical Trials Trials Drugs 52

BioPharma Drive: Drug Pricing

OCTOBER 21, 2024

Launched by PureTech and backed by well-known venture capital firms, the startup has raised $325 million since its debut this spring.

Drug Development 209

Drug Development Drugs 209

Drug Patent Watch

MARCH 4, 2025

The Unseen Heroes of Generic Drug Development: Pharmacovigilance As a generic drug developer, you're no stranger to the challenges of bringing affordable medications to market. But have you ever stopped to think about the unsung heroes of generic drug development?

Drug Development 52

Drug Development Drugs Government Production 52

BioPharma Drive: Drug Pricing

OCTOBER 6, 2023

The funding, which is part of ACT for ALS, will support expanded access studies of drugs developed by Prilenia Therapeutics, Clene Nanomedicine and Rapa Therapeutics.

Research 318

Research Drugs Drug Development 318

Drug Patent Watch

DECEMBER 30, 2024

The regulatory environment in Japan for generic drug development is complex and has undergone significant changes in recent years. Regulatory Authority: Pharmaceuticals and Medical Devices Agency (PMDA) The PMDA is the primary regulatory authority responsible for overseeing the drug approval process in Japan.

Drug Development 52

Drug Development Clinical Pharmacology Clinical Trials Pharmaceutical Companies 52

BioPharma Drive: Drug Pricing

MARCH 25, 2024

Worth about $138 million upfront, the deal is another example of pharma interest in new drugs for inflammatory conditions like Crohn’s.

Drug Development 167

Drug Development Drugs 167

BioPharma Drive: Drug Pricing

JUNE 20, 2023

The deal adds to recent M&A activity as well as signals pharma’s continued interest in pills for inflammatory conditions, which are meant to approach the potency of injectable therapies.

Drug Development 237

Drug Development Therapies Drugs 237

BioPharma Drive: Drug Pricing

AUGUST 25, 2023

Neumora’s filing late Friday, along with that of radiopharmaceutical startup RayzeBio earlier this week, could be an important test of the biotech IPO market.

Drug Development 246

Drug Development Marketing Drugs 246

BioPharma Drive: Drug Pricing

AUGUST 23, 2023

The funding for Rapport Therapeutics saw participation from a series of so-called crossover investors, many of which have pulled back from biotech startups in recent years.

Drug Development 245

Drug Development Drugs 245

BioPharma Drive: Drug Pricing

NOVEMBER 26, 2024

The brain drug developer is letting go of around 41 of its 238 employees, in a move the company says will help “align resources” with its strategic priorities.

Drugs 274

Drugs Drug Development 274

BioPharma Drive: Drug Pricing

MAY 29, 2024

An acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.

Drug Development 190

Drug Development Treatment Drugs 190

Collaborative Drug

JULY 22, 2024

Is Revolutionizing Drug Development. Holy Grail for Weight-Loss Drugs Is Sleep Apnea? DNA Discovery that Could Help Find Pancreatic Cancer Cure.

DNA 263

DNA Drugs Drug Development 263

BioPharma Drive: Drug Pricing

JANUARY 8, 2024

The proposed takeout follows a spate of dealmaking around antibody-drug conjugates, targeted cancer medicines that have lured AbbVie, Pfizer, Merck and Gilead.

Drug Development 196

Drug Development Drugs 196

BioPharma Drive: Drug Pricing

OCTOBER 14, 2024

Choosing the right clinical outcome assessments (COAs) is an important part of successfully advancing drug development and securing regulatory approval.

Drug Development 130

Drug Development Drugs 130

Drug Patent Watch

MARCH 3, 2025

Breaking Down Barriers: The Power of Global Research Collaborations in Generic Drug Development As the world grapples with the complexities of healthcare, one thing is clear: the need for innovative solutions has never been more pressing. The benefits of international collaborations in generic drug development are multifaceted.

International 52

International Drug Development Drugs Treatment 52

BioPharma Drive: Drug Pricing

JULY 16, 2024

The Merck KGaA spinout has a tau-regulating medicine it claims could be an “ideal therapy” for Alzheimer’s. The pitch has intrigued both healthcare investors and pharma venture arms.

Drug Development 184

Drug Development Regulations Therapies Drugs 184

Drug Target Review

DECEMBER 20, 2024

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

PPD

DECEMBER 16, 2024

Our annual look at the state of the drug development industry highlights a dual set of challenges complicating progress. Rising costs have become a persistent challenge for drug developers, driven by a combination of internal and external pressures that have intensified in recent years.

Drug Development 52

Drug Development Clinical Trials Compliance Trials 52

Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine. What is a Drug Patent?

Drugs 97

Drugs Drug Development Pharmaceuticals Production 97

Quanticate

AUGUST 2, 2024

Real-world evidence (RWE) is changing clinical drug development, bridging the gap between controlled clinical trial environments and the complexities of everyday patient experiences.

Drug Development 104

Drug Development Clinical Trials Drugs Trials 104

BioPharma Drive: Drug Pricing

DECEMBER 22, 2023

The deal would hand Bristol Myers, which has newly made neuroscience a therapeutic focus, an experimental treatment for schizophrenia.

Drug Development 196

Drug Development Treatment Drugs 196

BioPharma Drive: Drug Pricing

AUGUST 14, 2023

Stephen Apps discusses how technology can help improve the speed and quality of clinical research and why a dedicated, cross-functional approach is needed to maximize its value for smaller biotechs.

Drug Development 245

Drug Development Clinical Research Research Drugs 245

BioPharma Drive: Drug Pricing

SEPTEMBER 30, 2024

Among the investors in Aktis’ Series B round were Bristol Myers Squibb, Eli Lilly and Merck & Co., all of which have expanded their involvement in the radiopharma field.

Drug Development 157

Drug Development Drugs 157

BioPharma Drive: Drug Pricing

JUNE 21, 2024

A medicine Jazz acquired in 2019 missed the goal of a Phase 2 study. Elsewhere, Vanda rejected two takeover bids and Ashibio emerged from stealth with an antibody licensed from Gilead.

Drug Development 167

Drug Development Licensing Licensing Drugs 167

Fierce BioTech

SEPTEMBER 19, 2023

To predict whether new therapeutics will be safe and effective for humans, drug developers first test them in animal- and cell-based models as well as computational tools that are designed to appro | An introduction to Organ-on-a-Chip technology and how it can improve the quality of drugs entering the clinic.

Drug Development 115

Drug Development Drugs 115

BioPharma Drive: Drug Pricing

DECEMBER 20, 2023

Still, the complexities of the disease and of drug development have brought hard-felt losses. The Healey center is at the front of ALS research and care, earning acclaim from patients, doctors and scientists.

Research 356

Research Doctors Treatment Drug Development 356

Drug Patent Watch

DECEMBER 10, 2024

Generic drug development is a complex process that involves not only scientific and medical expertise but also adherence to strict legal and ethical standards. Scientific expertise plays a crucial role in ensuring that generic drugs are held to the same standards of quality, safety, and efficacy as their brand-name counterparts.

Drug Development 98

Drug Development Pharmacokinetics Compliance Drugs 98

BioPharma Drive: Drug Pricing

APRIL 10, 2024

The biotech is working on a preventive therapy for the immune disorder, known as FNAIT for short, while J&J is studying its drug nipocalimab as a treatment.

Drug Development 146

Drug Development Drugs Therapies Treatment 146

BioPharma Drive: Drug Pricing

AUGUST 22, 2023

Billing itself as both a scientific and investment partner, Foundery aims to provide research grants and drug development support to researchers developing new immunotherapies.

Research 246

Research Drug Research Drug Development Drugs 246